News | Implantable Cardioverter Defibrillator (ICD) | December 08, 2015

University Hospitals Brings Emblem S-ICD System to Cleveland’s East and West Sides

Two different hospitals perform first subcutaneous implants for sudden cardiac arrest patients

University Hospitals, Emblem S-ICD System, sudden cardiac arrest, SCA patients

December 8, 2015 — At Ahuja Medical Center, University Hospitals (UH) cardiologists recently implanted the Boston Scientific Emblem Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD) system, the first such procedure done at this hospital. The procedure was performed by Dina Sparano, M.D., a cardiac electrophysiologist at UH, together with Keith Kruithoff, M.D., in a patient who had survived a sudden cardiac arrest (SCA).

Across town, Sparano brought this latest version of the S-ICD to St. John Medical Center in Westlake, Ohio, the first Emblem S-ICD on Cleveland’s west side. The patient in this case was another survivor of SCA. The two procedures were performed days apart, representing significant advancements in cardiovascular care across the Cleveland area for UH.

SCA is a serious, life-threatening condition that happens abruptly and without warning. During SCA, the heart’s electrical system malfunctions causing dangerous, rapid heartbeats originating from the lower chambers of the heart. The heart’s mechanical activity fails and is no longer able to pump blood to the rest of the body. The lack of blood to the brain causes the person to lose consciousness quickly. If the person does not receive immediate treatment with defibrillation, brain damage and death can occur.

SCA accounts for over 325,000 deaths in the United States every year and is one of the leading causes of death. When death results, it is usually because life-saving therapy was not available in time. Implantable cardioverter-defibrillators are designed to detect this electrical disturbance and deliver an electric shock to the heart to restore a normal heartbeat. ICD therapy has been shown to effectively stop 95 percent or more of dangerously fast heart rhythms. With an ICD device, 19 out of 20 people will survive SCA.

The Emblem S-ICD System is the only defibrillator placed fully under the skin (subcutaneous) that provides protection from SCA without touching the heart or circulatory system, according to Boston Scientific. It is proven to be safe and efficacious in the treatment of SCA in appropriately selected patients. Having recently joined UH, Sparano brings a great deal of experience utilizing the S-ICD since its inception in clinical practice.

“The Emblem S-ICD represents the latest technology in a cardiac device that already sets itself apart for delivering life-saving therapy to patients at high risk for SCA on a minimally invasive platform. This device offers appropriately-selected patients maximal benefit at the lowest risk, and simply, is the perfect device for the right patient. I am excited and proud to say that through the UH Harrington Heart & Vascular Institute, we have access to such medical innovation that is both safe and effective, allowing us to provide the best care system-wide. The regularity of cardiology advancements being adopted at our medical centers is rapidly broadening.”

The device is designed to provide the same protection from SCA as traditional transvenous ICDs. However, the entirety of the Emblem S-ICD System sits just below the skin without the need for thin, insulated wires – known as leads – to be placed into the heart itself. This leaves the heart and blood vessels untouched, which may result in a less invasive treatment that avoids potentially serious short and long-term complications associated with placing leads in the heart.

As a second generation S-ICD, the EMBLEM S-ICD System provides patients with a smaller and thinner device that is projected to last 40 percent longer than the previous version, and is enabled for remote patient management.

The U.S. Food and Drug Administration (FDA) granted regulatory approval for the Emblem S-ICD system in March 2015.

For more information:

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Overlay Init